Eliza Hawkes

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.

Kate Manos, Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, Melinda Burgess, Niles Elizabeth Nelson, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, Chun Yew Fong, Eliza A Hawkes

Journal article  |  2023  |  Leukemia

Immune evasion, due to abnormal expression of programmed-death ligands 1 and 2 (PD-L1/PD-L2), predicts poor outcomes with chemoimm..

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.

Allison Barraclough, James T England, Diego Villa, Joel Wight, Greg Hapgood, Jason Conn, Nicole Wong Doo, Eric Wenlong Li, Michael Gilbertson, Briony Shaw, Mark J Bishton, Malik Saeed, Sumita Ratnasingam, Chathuri Abeyakoon, Geoff Chong, Shin Hnin Wai, Matthew Ku, Hui-Peng Lee, Kathryn Fleming, Constantine Tam, et al.

Journal article  |  2023  |  Haematologica

Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between 'low-grade' (Grade 1, ..

Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study.

Zhong Goh, Maya Latimer, Katharine L Lewis, Chan Y Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza A Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane

Journal article  |  2023  |  Clin Lymphoma Myeloma Leuk

BACKGROUND: There is no standard front-line therapy for older patients with classical Hodgkin lymphoma (cHL). We analyzed the clin..

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M Linton, Pamela McKay, Henry Chan, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Peter Browett, Xiaoyan Ke, Craig A Portell, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A Hawkes, Shir-Jing Ho, Keshu Zhou, et al.

Journal article  |  2023  |  Transplantation and Cellular Therapy

Clinical characteristics of Australian treatment-naive patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

James Nguyen, Cameron Wellard, Eliza Chung, Chan Y Cheah, Michael Dickinson, Nicole Wong Doo, Colm Keane, Dipti Talaulikar, Leanne Berkahn, Susan Morgan, Nada Hamad, Tara Cochrane, Anna M Johnston, Cecily Forsyth, Stephen Opat, Allison Barraclough, Howard Mutsando, Sumita Ratnasingam, Pratyush Giri, Erica M Wood, et al.

Journal article  |  2022  |  EUROPEAN JOURNAL OF HAEMATOLOGY

Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been syste..

Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

Diva Baggio, Cameron Wellard, Eliza Chung, Dipti Talaulikar, Colm Keane, Stephen Opat, Pratyush Giri, Adrian Minson, Chan Yoon Cheah, Tasman Armytage, Denise Lee, Geoffrey Chong, Anna Johnston, Tara Cochrane, Neil Waters, Nada Hamad, Erica M Wood, Eliza A Hawkes

Journal article  |  2022  |  LEUKEMIA & LYMPHOMA

Bruton’s tyrosine kinase inhibitors (BTKi) have an established role in the management of patients with relapsed/refractory mantle ..

The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.

Angie Mae Rodday, Susan K Parsons, Jenica N Upshaw, Jonathan W Friedberg, Andrea Gallamini, Eliza Hawkes, David Hodgson, Peter Johnson, Brian K Link, Eric Mou, Kerry J Savage, Pier Luigi Zinzani, Matthew Maurer, Andrew M Evens

Journal article  |  2022  |  J Clin Oncol

PURPOSE: The International Prognostic Score (IPS) has been used in classic Hodgkin lymphoma (cHL) for 25 years. However, analyses ..

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Zhong Goh, Maya Latimer, Katharine L Lewis, Chan Yoon Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane

Journal article  |  2022  |  BLOOD

Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Angie Mae Rodday, Susan K Parsons, Jonathan W Friedberg, Andrea Gallamini, Eliza Hawkes, David C Hodgson, Peter Johnson, Brian K Link, Eric Mou, Kerry J Savage, Jenica Upshaw, Pier Luigi Zinzani, Matthew J Maurer, Andrew M Evens

Journal article  |  2022  |  Blood

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.

Anas Younes, John M Burke, Bruce D Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe Hahn, Eliza A Hawkes, Cyrus Khan, Izidore S Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam LS Yuen, Aparna Raval, Mahesh Shivhare, Tina G Nielsen, Gila Sellam, Jeff P Sharman

Journal article  |  2022  |  Blood Adv

Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is the current standard therapy for patients wit..